HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma

This item is licensed under: Creative Commons Attribution 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1002/jgh3.12339


Title: Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
Authors: Shigesawa, Taku Browse this author
Suda, Goki Browse this author →KAKEN DB
Kimura, Megumi Browse this author
Shimazaki, Tomoe Browse this author
Maehara, Osamu Browse this author
Yamada, Ren Browse this author
Kitagataya, Takashi Browse this author
Suzuki, Kazuharu Browse this author
Nakamura, Akihisa Browse this author
Ohara, Masatsugu Browse this author
Umemura, Machiko Browse this author
Kawagishi, Naoki Browse this author
Nakai, Masato Browse this author
Sho, Takuya Browse this author
Natsuizaka, Mitsuteru Browse this author →KAKEN DB
Morikawa, Kenichi Browse this author
Ogawa, Koji Browse this author →KAKEN DB
Sakamoto, Naoya Browse this author →KAKEN DB
Keywords: angiopoietin-2
fibroblast growth factor 19
hepatocellular carcinoma
sorafenib
treatment outcome
Issue Date: Oct-2020
Publisher: John Wiley & Sons
Journal Title: JGH open
Volume: 4
Issue: 5
Start Page: 880
End Page: 888
Publisher DOI: 10.1002/jgh3.12339
Abstract: Background Sorafenib and lenvatinib are first-line systemic therapies for unresectable hepatocellular carcinoma (HCC). However, the criteria for their selection remain unclear. Methods We identified patients with unresectable HCC who were treated with sorafenib or lenvatinib between August 2009 and January 2019 at the Hokkaido University Hospital. Patients who continued treatment for >2 months, underwent evaluation by computed tomography every 2-3 months, and had complete clinical data were included. Responders were patients with objective response (OR) for lenvatinib and patients with stable disease (SD) exceeding 6 months (long-SD) or OR for sorafenib. The predictive factors for treatment response, including fibroblast growth factor (FGF)19 and 21, angiopoietin 2 (ANG2), hepatocyte growth factor, and vascular endothelial growth factor, were evaluated. Results Overall, 27 and 29 patients treated with lenvatinib and sorafenib, respectively, were included. The responders for lenvatinib and sorafenib were 63% (17/27) and 38% (11/29), respectively. No significant predictive factors for treatment response were identified in patients treated with sorafenib. However, baseline serum FGF19 and ANG2 levels were significantly associated with treatment response to lenvatinib. All (9/9) patients with low baseline ANG2 and FGF19 levels who received lenvatinib achieved OR. Conversely, the OR was low (13%; 1/9) in patients with high baseline ANG2 and FGF19 levels. Responder rate was 40% (2/5) in patients with high baseline ANG2 and FGF19 levels who received sorafenib. Conclusion This study is, to our knowledge, the first to demonstrate that baseline ANG2 and FGF19 levels may aid in selecting optimal systemic therapy for patients with unresectable HCC.
Rights: https://creativecommons.org/licenses/by/4.0/
Type: article
URI: http://hdl.handle.net/2115/79632
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University